You are required to be logged in to access the full website
Click here if you have forgotten your username or password
Therapy Areas
30 September 2026 - Medicine company Eli Lilly and Company (NYSE: LLY) revealed on Wednesday that it has achieved positive 48-week Phase 2b results for EloraTZP, its investigational combination of eloralintide and tirzepatide, showing greater weight ...
30 September 2026 - US pharmaceutical company Merck & Co Inc (NYSE:MRK), known as MSD outside the US and Canada, on Wednesday announced positive Phase 2b results for tulisokibart, an investigational anti-TL1A monoclonal antibody, in patients with...
30 September 2026 - Biotechnology company Genentech, a member of the Roche Group (SIX: RO, ROG) (OTCQX: RHHBY), announced on Wednesday that the US Food and Drug Administration (FDA) has accepted its New Drug Application for fenebrutinib under priorit...
30 September 2026 - Belgian biopharmaceutical company Oxurion NV (Euronext Brussels:OXUR) announced on Wednesday that it has entered into exclusive negotiations to acquire the business and operating assets of Eclevar, a French contract research organ...
30 September 2026 - Late-stage biopharmaceutical company DBV Technologies (Euronext:DBV) (Nasdaq:DBVT) announced on Wednesday that it has submitted a Biologics License Application to the US Food and Drug Administration (FDA) and requested Priority Re...
30 September 2026 - UTR Therapeutics Inc, a New York-based biotech company, announced on Tuesday that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation to 3'UTRMYCN M1-14 (UTRxMYCN M1-14) for the treatment of soft tis...
29 September 2026 - Biopharmaceutical company AstraZeneca plc (STO:AZN) (LON:AZN) (NYSE:AZN) announced on Tuesday that it has agreed to invest USD2bn in newly issued equity in biopharmaceutical oncology company Summit Therapeutics Inc (NASDAQ:SMMT) t...